Apply to trial NCT06803693

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

The purpose of this study is to compare the efficacy and safety of genotype-guided targeted agents in combination with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola RCHP-X) versus Pola RCHP in Chinese patients with previously untreated diffuse large B-cell lymphoma (DLBCL).

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening